


Manager PR & Communications Jan Phillip Denkers

Evotec announces CEO transition
Evotec SE announced that after close to 15 years of successful service, CEO Dr Werner Lanthaler has informed the company, that he will not continue ...
Read more …
Senator Dr. Melanie Leonhard visits Evotec
Evotec SE announced that new high-throughput screening (“HTS”) facilities at the Company’s headquarters in Hamburg, as well as additional equipment for investigating ...
Read more …
Evotec enters partnership with Hannover Medical School
Evotec SE announced that the Company has entered a partnership with Hannover Medical School (“MHH”), one of the leading German universities, to ...
Read more …
Evotec initiates ground-breaking for new biologics facility
Evotec SE today officially launched the construction of its J.POD® biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. J.POD® Toulouse, ...
Read more …
Evotec, Boehringer Ingelheim and bioMérieux cooperate
Evotec SE, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and bioMérieux, a world leader in in vitro diagnostics, announced today that they have formed a ...
Read more …
Evotec: strategic roadmap towards precision medicine
Evotec SE presents at its virtual Capital Markets Day how artificial intelligence (“AI”) and machine learning (“ML”) enabled precision technologies in discovery ...
Read more …
Evotec: € 7.5 m grant for development of COVID-19 therapeutic
Evotec SE announced that the Company has been selected by the German Federal Ministry of Education and Research (“BMBF”) to receive a grant for the ...
Read more …
Evotec receives US$ 18 m grant for women's health
Evotec SE announced that the Company has received a US$ 18 m grant from the Bill & ...
Read more …
Evotec Initiates US IPO
Evotec expects to grant the underwriters a 30-day option to purchase up to an additional 3,300,000 ADSs. The sale of the ADSs and the issuance ...
Read more …
Evotec: Collaboration with Bristol Myers Squibb
Evotec SE announced that its collaboration with Bristol Myers Squibb has been expanded to include a new cell type, triggering a payment of $ 9.0 ...
Read more …
Just - Evotec Biologics opens J.POD® 1 US
Evotec SE announced the opening of the company’s late-stage clinical and commercial biologics cGMP manufacturing facility (J.POD® 1 US) in Redmond, Washington. ...
Read more …
Evotec creates long-term growth opportunities
Evotec SE announced that Evotec has added significant opportunities for further, long-term growth by acquiring the Verona site from GlaxoSmithKline SpA (“GSK”). ...
Read more …- 1
- 2